Nanotech Stock Directory Features publicly traded companies developing new technology in Renewable Energy, Homeland Security, Biotech, Water

Nanotech Stock Directory Features publicly traded companies developing new technology in Renewable Energy, Homeland Security, Biotech, Water and other sectors

Delta B.C. – March 31, 2010 www.NanotechnologyInvestment.com, a leading investor and industry portal for the Nanotechnology sector, within Investorideas.com announces the updated nanotech stocks directory for investors.

The directory features global nanotech publicly traded companies that are developing new technology in energy, Homeland Security, Biotech, water and other sectors.

Nanotech Stock List April 2010

Preview:

3M Co. (NYSE:MMM) 3M scientists and researchers are exploring a new world at the nanometer level, where materials exhibit unique physical, chemical and biological properties. These unusual properties are already being exploited in our hard coatings, dental restoratives and brightness-enhancing optical films (used in LCD displays). Many 3M technology platforms, including adhesives and pharmaceuticals, are being influenced by the emergence of nano-sized particles.

A123 Systems, Inc. (NasdaqGM:AONE) develops and manufactures advanced lithium-ion batteries and battery systems for the transportation, electric grid services and consumer markets. Founded in 2001 and headquartered in Massachusetts, A123 Systems’ proprietary nanoscale electrode technology is built on initial developments from the Massachusetts Institute of Technology.

ABB Ltd. (NYSE:ABB) is a leader in power and automation technologies that enable utility and industry customers to improve performance while lowering environmental impact. The ABB group of companies operates in some 100 countries and employs approximately 120,000 people. The ABB Corporate Research facilities in both Sweden and Poland are currently working on nanotechnology and advanced materials technologies.

Abraxis Bioscience (NasdaqGS:ABII) is a fully integrated biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the world’s first and only protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its proprietary tumor targeting system known as the nabâ„¢ Technology platform.

Accelrys (NasdaqGM:ACCL) develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Our customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. The Accelrys Nanotechnology Consortium has delivered a range of cutting-edge software tools to meet the challenges of rational nanodesign. Following a very successful Phase I, supported by over 30 members worldwide, Phase II is now under way. Phase II focuses on developing tools and protocols that bridge the gap between atomistic simulations and engineering applications in the area of reaction kinetics